A preponderance of clinical evidence supports a significant public health benefit for prostate-specific antigen (PSA)–based screening and early detection of prostate cancer in appropriately counseled and selected men. Population-based screening…
Prostate cancer risk stratification based on conventional clinical and pathologic characteristics alone may misclassify a proportion of men at various stages of the disease process. Many gene-based assays have emerged…
The Prostate Health Index is a Food and Drug Administration–approved blood test combining total, free, and [-2]pro prostate-specific antigen with greater specificity than free and total prostate-specific antigen for clinically…
Kevin R. Loughlin, MD, MBA, Editor This issue of Urologic Clinics is devoted to biomarkers. The writer Sean O’Casey said, “Nothing is so powerful as an idea whose time has…
Samir S. Taneja, MD, Consulting Editor This wonderful issue of Urologic Clinics explores the current and evolving role of biomarkers in urologic oncology. While we often consider biomarkers only in…
